Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.54 |
| ▸ | NPY1R | P25929 | 10/20 | 0.54 |
| ▸ | NPY2R | P49146 | 7/20 | 0.54 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG | P07510 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 1/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461967 | 1.00 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RCHRNA1 | |
| SCHEMBL24919552 | 0.90 | NPY4R (0.57) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL30309227 | 0.90 | NPY4R (0.67) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30589456 | 0.89 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30592738 | 0.89 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30309304 | 0.89 | NPY4R (0.65) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29461983 | 0.89 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31412180 | 0.89 | QRFPR (0.45) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31467761 | 0.89 | SLC15A2 (0.46) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30746799 | 0.88 | C5AR1 (0.47) | NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12297502-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268724-B2 | Methods and compositions for the prevention or treatment of Barth Syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250109167-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230033758-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-02 | — | — | US | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11420998-B2 | Aromatic-cationic peptides and methods for using same | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11366104-B2 | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-4005582-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11312993-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | COL2A1, ALPI, COL14A1 | NPY4R 223/4885NPY5R 484/4885NPY1R 735/4885 |
| US-20250109167-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | NLN, OAT, HAGH | NPY4R 693/4885NPY5R 976/4885NPY1R 649/4885 |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | ARG2, ARGLU1, BCAT1 | NPY4R 2600/4885NPY5R 1341/4885NPY1R 872/4885 |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | TNNI3, TNNT2, FABP3 | NPY4R 2454/4885NPY5R 2704/4885NPY1R 1553/4885 |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | NPY4R 223/4885NPY5R 484/4885NPY1R 735/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | NPY4R 2905/4885NPY5R 2474/4885NPY1R 2251/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | NPY4R 2905/4885NPY5R 2474/4885NPY1R 2251/4885 |
| US-11420998-B2 | Aromatic-cationic peptides and methods for using same | ARG2, ARGLU1, ARG1 | NPY4R 824/4885NPY5R 1077/4885NPY1R 523/4885 |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | ARG2, MTPN, TNNT2 | NPY4R 3734/4885NPY5R 3526/4885NPY1R 3368/4885 |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | NPY4R 223/4885NPY5R 484/4885NPY1R 735/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | NPY4R 4783/4885NPY5R 4367/4885NPY1R 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.